Translational Cancer Research

Journal Title：Translational Cancer Research

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.

转化癌症研究 (Transl Cancer Res TCR；印刷 ISSN：2218-676X；在线 ISSN 2219-6803；http://tcr.amegroups.com/) 是一本开放获取、同行评审的期刊，收录于科学引文索引扩展版 (SCIE)。TCR 发表新型治疗干预的实验室研究以及评估癌症新治疗模式的临床试验；新型研究调查的结果，这些调查将实验室和临床环境连接起来，包括风险评估、细胞和分子表征、人类癌症的预防、检测、诊断和治疗，总体目标是改善癌症患者的临床护理。TCR 的重点是原创的、同行评审的、基于科学的研究，这些研究成功地推动了临床医学朝着改善患者生活质量的目标发展。编辑和由科学家、临床科学家以及其他专家组成的国际顾问团将确保 TCR 文章达到高质量标准。我们接受原创文章以及评论文章、社论和简短文章。

Translational Cancer Research创刊于2012年，由AME Publishing Company出版商出版，收稿方向涵盖ONCOLOGY全领域，此期刊水平偏中等偏靠后，在所属细分领域中专业影响力一般，过审相对较易，如果您文章质量佳，选择此期刊，发表机率较高。平均审稿速度 ，影响因子指数1.5，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。